EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer

Cancer

Volumn 115, Issue 12, 2009, Pages 2684-2692

  Kamat, Aparna A ^a   Coffey, Donna ^b   Merritt, William M ^a   Nugent, Elizabeth ^a   Urbauer, Diana ^a   Lin, Yvonne G ^a   Edwards, Creighton ^c   Broaddus, Russell ^a   Coleman, Robert L ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Endometrial cancer; EphA2; Estrogen receptor; Ki 67; Progesterone receptor

Indexed keywords

EPHRIN RECEPTOR A2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MYOMETRIUM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPHA2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 67649232592     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24335     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Rose P. Endometrial carcinoma. N Engl J Med. 1996;335:640-649. (Pubitemid 26277956)
3. Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene. 2000;19:5614-5619.
4. Lamorte L, Park M. The receptor tyrosine kinases: role in cancer progression. Surg Oncol Clin North Am. 2001;10:271-288. (Pubitemid 32472530)
5. Walker-Daniels J, Hess AR, Hendrix MJC, Kinch MS. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol. 2003;162:1037-1042. (Pubitemid 36350648)
6. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Moll Cell Biol. 2005;6:462-475. (Pubitemid 40780558)
7. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001;61:2301-2306. (Pubitemid 32692063)
8. Walker-Daniels J, Coffman K, Azimi M, et al. Overexpression of the EphA2 receptor tyrosine kinase in prostate cancer. Prostate. 1999;41:275-280.
9. Kinch MS, Moore MB, Harpole DH Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res. 2003;9:613-618. (Pubitemid 36182592)
10. Thaker PH, Deaver M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004;10:5145-5150. (Pubitemid 39099789)
11. Kamat AA, Fletcher M, Gruman LM, et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2006;12:1707-1714.
12. Lindberg RA, Hunter T. cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Moll Cell Biol. 1990;10:6316-6324. (Pubitemid 120004574)
13. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 2002;62:2840-2847. (Pubitemid 34525769)
14. Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res. 2001;61:3250-3255. (Pubitemid 32695007)
15. Lu M, Miller KD, Gokmen-Polar Y, Jeng M, Kinch MS. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 2003;63:3425-3429. (Pubitemid 36735904)
16. Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007;109:332-339. (Pubitemid 46106248)
17. Andres AC, Reid HH, Zurcher G, Blaschke RJ, Ablrecht D, Ziemiecki A. Expression of 2 novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene. 1994;9:1461-1467. (Pubitemid 24123665)
18. Pandey A, Shao H, Marks RM, Polverinin PJ, Dixit VM. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-a-induced angiogenesis. Science. 1995;268:567-569.
19. Sherman ME, Bur ME, Kurman RJ. P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26:1268-1274.
20. Chambers JT, MacLusky N, Eisenfield A, Kohorn EI, Lawrence R, Schwartz PR. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol. 1990;38:59-65. (Pubitemid 20206227)
21. Morris PC, Anderson JR, Anderson B, Butler RE. Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol. 1995;56:406-411.
22. Zelinski DP, Zantek ND, Walker-Daniels J, Peters MA, Taparowsky EJ, Kinch MS. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase. J Cell Biochem. 2002;85:714-720. (Pubitemid 34462782)
23. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736-1744. (Pubitemid 29269242)
24. Landen CN Jr, Lu C, Han LY, et al. Efficacy and antivascular effects of EphA2 reduction with an agonist antibody in ovarian cancer. J Natl Cancer Inst. 2006;98:1558-1570. (Pubitemid 44680907)
25. Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006;5:1708-1713. (Pubitemid 46256653)